Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
暂无分享,去创建一个
B. Scheithauer | J. O'fallon | P. Burger | R. Jenkins | A. Yates | A. Perry | Justin S. Smith | T. Borell | D. Kimmel | J. S. Smith | S. Hosek | H. K. Lee | Hyun K. Lee | A. Yates | Sandra M. Hosek
[1] B. Scheithauer,et al. Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. , 1999, American journal of clinical pathology.
[2] D. Louis,et al. The human glia maturation factor-gamma gene: genomic structure and mutation analysis in gliomas with chromosome 19q loss , 1999, Neurogenetics.
[3] B. Scheithauer,et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.
[4] D. Louis,et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.
[5] W. Liu,et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. , 1998, Genomics.
[6] D. Bostwick,et al. A molecular cytogenetic analysis of 7q31 in prostate cancer. , 1997, Cancer research.
[7] D. Louis,et al. Molecular Genetic Evidence for Subtypes of Oligoastrocytomas , 1997, Journal of neuropathology and experimental neurology.
[8] G. Mohapatra,et al. Detection of p16 Gene Deletions in Gliomas: A Comparison of Fluorescence in Situ Hybridization (FISH) Versus Quantitative PCR , 1997, Journal of neuropathology and experimental neurology.
[9] A. Yang,et al. Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.
[10] L. Rorke. Pathologic diagnosis as the gold standard , 1997, Cancer.
[11] D. Louis,et al. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. , 1996, Oncogene.
[12] D. Louis,et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. , 1996, Journal of neurosurgery.
[13] M. Schwab,et al. Genomic instability in Ip and human malignancies , 1996, Genes, chromosomes & cancer.
[14] D. Louis,et al. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. , 1996, Cancer genetics and cytogenetics.
[15] G. Krol,et al. Low-grade oligodendroglioma responds to chemotherapy , 1996, Neurology.
[16] D. Louis,et al. A tiger behind many doors: multiple genetic pathways to malignant glioma. , 1995, Trends in genetics : TIG.
[17] D. Louis,et al. Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. , 1995, Genomics.
[18] J. Rey,et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors , 1995, International journal of cancer.
[19] V. Ganju,et al. Region‐specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma , 1995, Genes, chromosomes & cancer.
[20] F. Waldman,et al. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization , 1995, International journal of cancer.
[21] D. Louis,et al. Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma , 1995, Journal of neuropathology and experimental neurology.
[22] G. Reifenberger,et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.
[23] T. Cascino,et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Lenartz,et al. Deletion mapping of chromosome 19 in human gliomas , 1994, International journal of cancer.
[25] R. Wellenreuther,et al. Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. , 1994, Cancer research.
[26] B. Scheithauer,et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] P. Kelly,et al. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo‐astrocytomas , 1992, Genes, Chromosomes and Cancer.
[28] I. Petersen,et al. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. , 1992, Cancer research.
[29] David W. Smith,et al. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. , 1992, Journal of neurosurgery.
[30] C. Junien,et al. Report of the committee on chromosome and gene loss in human neoplasia , 1991 .
[31] A. Kiss,et al. Abnormalities of chromosome 1 in relation to human malignant diseases. , 1989, Cancer genetics and cytogenetics.
[32] J. Cairncross,et al. Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.
[33] N. B. Atkin. Chromosome 1 aberrations in cancer. , 1986, Cancer genetics and cytogenetics.
[34] O. G. Dodge,et al. Histological Typing of tumours of the Central Nervous System , 1981, British Journal of Cancer.
[35] D. Cox. Regression Models and Life-Tables , 1972 .
[36] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[37] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .